Investment

Swiss family office leads big health investment

A little known Swiss-based family office has led a sizable investment into a US-based anti-ageing health group, which is also backed by some big venture funds.

GISEV Family Office, a Lugano-based family office for members of the Giuliani family, who control an eponymous Italian-based pharmaceutical company, invested in the New York City-based Elysium Health

Set up in 2017, GISEV led the Series C round worth $40 million in Elysium, which has received more than $70 million in outside funding since being set up in 2014. The health group sells an anti-ageing dietary supplement called Basis. Its website says it is also launching a biological age home test product in January called Index. Both products are sold over the internet. 

Other backers of Elysium include General Catalyst, a Cambridge, Massachusetts-based venture fund, Jim Breyer’s Breyer Capital, and Mayo Clinic Ventures. 

Brothers Giammaria and Germano Giuliani are the fourth generation main shareholders of Giuliani, a Milan-based pharmaceutical company, which among other products makes the anti-hair loss and care drug Bioscalin. 

Lugano-based Giammaria Giuliani along with his wife Sabrina also have a foundation, which, according to its website, finances medical and scientific research projects. 

Subscribe

You will need a Premium Plus Subscription to access this database.

Exclusive news, analysis and research on global family enterprise and private investment offices.

Access to the most comprehensive fully interactive database on global family offices, principal investment offices, and family enterprises.

Check Deal Data, Senior Staff, and New Analysis on more than 500 family/principal investment and holding groups

Already have an account? Login

Subscribe

You need at least a Premium Subscription to read this article.

The most comprehensive information service on the global family enterprise world, featuring exclusive news, analysis, research and data on global family enterprises, family offices, and private investment offices.

Premium

£299

per year

  • Exclusive reports, analysis and commentary
  • Exclusive access to family/private investment office deal information
  • Exclusive interviews with principals and senior management of family/investment offices
SUBSCRIBE NOW

Premium+

£399

per year

  • Access to All of Premium
  • Access to all of FamilyCapital Analytics, our interactive database with more than 500 detailed profiles of family investment groups

More Info

SUBSCRIBE NOW

Already have an account? Login

You've reached the end.

Continue reading free articles by registering as a Member.
Or choose a Premium Plan.

Membership

Free

  • Exclusive reports, analysis and commentary
REGISTER NOW

Premium

£299

per year

  • Exclusive reports, analysis and commentary
  • Exclusive access to family/private investment office deal information
  • Exclusive interviews with principals and senior management of family/investment offices
SUBSCRIBE NOW

Premium+

£399

per year

  • Access to All of Premium
  • Access to all of FamilyCapital Analytics, our interactive database with more than 500 detailed profiles of family investment groups

More Info

SUBSCRIBE NOW

Already have an account? Login

Leave a Reply